REG - Physiomics PLC - Options Award

PhysiomicsAnnouncement

06/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240206:nRSF0885Ca&default-theme=true

RNS Number : 0885C  Physiomics PLC  06 February 2024

6 February 2024

 

Physiomics plc

("Physiomics" or the "Company")

 

Options Award

 

Physiomics plc (AIM: PYC), announces an award of share options (the "Options")
over ordinary shares of 0.4p each in the Company ("Ordinary Shares").  The
Company considers that it is important to incentivise its key executives to
create shareholder value and, as such, today the Board has approved the award
of the following options to Dr Peter Sargent under the Company's existing
share option scheme (the "Scheme"):

1.  1,354,725 Options with exercise price of 1.55p, being the greater of (i)
the average closing price for the three dealing days immediately preceding the
date of grant; and (ii) the closing price on the dealing day immediately prior
to the date of grant.  Half of these Options vest on award and half six
months from the date of award

2.  1,354,725 Options with exercise price of 2.55p, being the exercise price
calculated in (1) above plus 1p.  One third of these Options vest on each
anniversary of the date of award (so none are exercisable immediately, 33.3%
from 6 Feb 2025, 66.7% from 6 Feb 2026 and 100% from 6 Feb 2027)

3.  1,354,725 Options with exercise price of 3.55p, being the exercise price
calculated in (1) above plus 2p.  These Options vest over the same time
periods as described under (2) above.

All Options can be exercised within 10 years of the date of grant.

Following this issue, the Directors will hold Options over Ordinary Shares in
the Company in accordance with the table below:

 

 Option holder        # Options           Exercise price(p)                      Date of expiry

 P Sargent               1,354,725                         1.55                  05-Feb-34
 P Sargent               1,354,725                         2.55                  05-Feb-34
 P Sargent               1,354,725                         3.55                  05-Feb-34
 Total P Sargent         4,064,175

 C Chassagnole              322,615                        6.17                  23-Mar-25
 C Chassagnole              659,641                        2.50                  27-Feb-27
 C Chassagnole              350,000                        5.35                  26-Mar-28
 C Chassagnole              267,000                        3.16                  26-Mar-29
 C Chassagnole              694,287                        7.55                  01-Mar-31
 Total C Chassagnole     2,293,543

 J Millen                   520,000                        5.35                  26-Mar-28
 J Millen                   400,000                        3.16                  26-Mar-29
 J Millen                   985,454                        7.55                  01-Mar-31
 Total J Millen          1,905,454

In addition, Dr Jim Millen is interested in 1,884,393 Ordinary Shares
(equivalent to approximately 1.39% of the Company's currently issued share
capital); Dr Christophe Chassagnole is interested in 1,102,723 Ordinary Shares
(equivalent to approximately 0.81% of the Company's currently issued share
capital).

The total number of Ordinary Shares in issue remains unchanged at 135,472,478
Ordinary Shares with voting rights attached (one vote per Ordinary Share).
There are no Ordinary Shares held in treasury. This total voting rights figure
may be used by shareholders as the denominator for the calculations by which
they will determine whether they are required to notify their interests in, or
a change to their interest in, Physiomics under the Disclosure and
Transparency Rules.

 

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

The notification below, made in accordance with the requirements of the EU
Market Abuse Regulation, provides further detail in respect of the transaction
as described above.

 

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Dr Peter Sargent
 2   Reason for the notification
 a)  Position/status                                              CEO
 b)  Initial notification /Amendment                              Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Physiomics PLC (the "Issuer")
 b)  LEI                                                          213800A71DSZ6ABMTQ91
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Options over Ordinary Shares

     Identification code                                          GB00BDR6W943

 b)  Nature of the transaction                                    Issue of options
 c)  Price(s) and volume(s)
                                                                                    Price(s)          Volume(s)
                                                                                    1.55 pence        1,354,725
                                                                                    2.55 pence        1,354,725
                                                                                    3.55 pence        1,354,725

 d)  Aggregated information

     - Aggregated volume                                          4,064,175 ordinary shares

     - Price                                                      Average price of 2.55 pence

 e)  Date of the transaction                                      06 February 2024
 f)  Place of the transaction                                     London, AIM

 

 

This announcement is released by Physiomics plc and contains inside
information for the purposes of Article 7 of the Market Abuse Regulation (EU)
596/2014 (MAR), and is disclosed in accordance with the Company's obligations
under Article 17 of MAR.

 

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines cutting edge PKPD and QSP modelling and data science
techniques, along with deep biology expertise, to help biotech and pharma
companies streamline their drug development journeys.

Our approach is to derive insight from all relevant data in order to de-risk
decision making and optimise design research across discovery, pre-clinical
and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology,
the Physiomics team has informed the development of over 100 commercial
projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas,
Bicycle Therapeutics, Numab Therapeutics & CRUK.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUPUPPPUPCGRA